GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
Business & Industry News Channel
This submission comes after two successful phase III clinical trials conducted between 2020 and 2021.